Venus Remedies Limited, one of India's top 20 R&D spenders and a research-driven pharmaceutical company, proudly announced the renewal of recognition for its in-house Research and Development (R&D) unit by the Department of Scientific and Industrial Research (DSIR), Ministry of Science & Technology, Government of India. This renewal underscores Venus Remedies' commitment to innovation, excellence in research, and its significant contributions to healthcare.

With 15 patented products brought to market and several others in the pipeline, VRL's R&D portfolio demonstrates a progressive approach to drug development. Venus Remedies Limited has consistently invested in research and development. The company invested 3.53% of its total sales in R&D, from which it has generated 5.25% of its total revenue, which stood at Rs 575.18 crore in FY 2021-22. The R&D spend for the same period amounted to Rs. 20.31 crores.

"Our in-house R&D unit has been at the forefront of pioneering research and development initiatives," said Mr. Saransh Chaudhary, CEO of Venus Medicine Research Centre and President of Global Critical Care at Venus Remedies. "This renewal of recognition from DSIR reinforces our position as a research-driven pharmaceutical company dedicated to bringing innovative and effective solutions to address global healthcare needs."

The medical research center is well-equipped with Good Laboratory Practice (GLP) accredited labs to cater to unmet medical needs, innovative breakthroughs to advance healthcare solutions, and state-of-the-art capabilities to accomplish human cures. Besides the fundamental development & research it delves in, spreading healthcare awareness on critical subject matters, including the Anti-Microbial Resistance (AMR), remains a priority.

With the renewal of recognition from DSIR and its ongoing efforts to combat antimicrobial resistance, Venus Remedies Limited solidifies its position as a leading research-driven pharmaceutical company, dedicated to excellence in research and bringing innovative medical solutions to address global healthcare challenges.